May 17, 2013 – During the month of October 2013, MitoQ® will donate 15% of all proceeds to one of the leading national education and support organizations, the National Breast Cancer Foundation (NBCF). NBCF’s mission is to save lives through early detection and to provide mammograms for those in need. This includes increasing awareness through education, providing diagnostic breast care services for those in need, supporting breast cancer research programs, and providing nurturing support services.
What is MitoQ®:
MitoQ® is a new anti-aging face cream proven to be the most potent antioxidant on the market to date. Officially launched in the United States in spring 2013, MitoQ® has been challenging the international skin care industry with a new level of efficacy. It is the only topical cream proven to deliver ubiquinone to mitochondria at levels shown to have an immense effect in rejuvenating the cells, encouraging the natural production of collagen and elastin and leaving skin looking radiant with a lit-from-within glow.
Why it’s different:
The MitoQ® molecule, mitoquinol, the key ingredient in the MitoQ® facial cream, is a recognized and patented invention that is proven to penetrate the mitochondria and is known to be 1,000x more potent than CoQ (a molecule used in the world’s best anti-aging products). MitoQ® is the result of over ten years of research and development. It is the work of Dr Michael Murphy, Mitochondrial Biology Unit, Cambridge and Professor Rob Smith Chemistry Department, Otago University, New Zealand. In a cutting-edge development a unique electrostatic penetration system is used to deliver antioxidant to the cells mitochondria. Neutralizing free radicals where they are produced and therefore stopping the skin aging process and healing prior damage.
About MitoQ® Limited:
Founded in 2005, MitoQ® Limited, is a wholly owned New Zealand subsidiary of Antipodean Pharmaceuticals Inc, a development stage pharmaceutical company. This dynamic bio-tech company works with a panel of experts to refine and bring to market breakthrough innovations, setting new standards in the pharmaceutical and cosmeceutical industries. CEO Kenneth Taylor has a doctorate in Pharmaceutical Chemistry and a Fellowship in Pharmacology and Experimental Therapeutics from The Johns Hopkins University School of Medicine, Baltimore, Maryland. He subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. During his professional career he held the position of Managing Director at various global Roche affiliates and converted Syntex into Roche Bioscience research center. For more information, please visit www.MitoQ.com
About the National Breast Cancer Foundation, Inc®:
Recognized as one of the leading breast cancer organizations in the world, the National Breast Cancer Foundation’s (NBCF) mission is to save lives through early detection and to provide mammograms for those in need. A recipient of Charity Navigator’s highest 4-star rating for nine years, NBCF provides women Help for Today…Hope for Tomorrow® through its National Mammography Program, Beyond The Shock®, Early Detection Plan, MyNBCF online support community, and breast cancer research programs. For more information, please visit www.nbcf.org.